Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)

NCT05768711 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: Venetoclax

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]